DC infusion 3 hours post-tMCAO did not affect infarct size or recruitment of CD68-positive immune cells at 24 hours (Figure 5), suggesting that DC treatment did not significantly alter the initial innate immune response to stroke injury within this time frame. This evidence concerns the gene CD68 and stroke disorder.